MNKD MannKind Corporation

By Inti Landauro

PARIS--French pharmaceutical giant Sanofi S.A. (SAN.FR) and its U.S. partner MannKind Corp. (MNKD) Tuesday said they started selling in the U.S. an inhaled insulin they developed.

The new drug called Afrezza was approved by the U.S. Food and Drug Administration to control high blood sugar in adults with type one and type two diabetes, the companies said in a statement.

Write to Inti Landauro at inti.landauro@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires